NSG/522 Week 6: Neurological and Psychological Medications, sample paper

She Asked for Alprazolam: Choosing Escitalopram Over a Benzodiazepine for Generalized Anxiety Disorder in a 34-Year-Old Accountant

[Student Name]

University of Phoenix

NSG/522: Advanced Pharmacology

Week 6 Assignment

[Instructor Name]

[Date]

Composite patient written as a model document. No real patient is described.

A composite 34-year-old accountant came to her nurse practitioner after eight months of worry she could not control, about work deadlines, her parents' health and money, even when things were going well. She had trouble falling asleep, tense shoulders, irritability and difficulty concentrating, and she had begun leaving work early on bad days. Her GAD-7 score was 15, and her PHQ-9 score was 8, with no thoughts of self-harm. She drank two glasses of wine most evenings "to wind down." Her thyroid function and a medication review were unremarkable. She asked directly for alprazolam, which a friend took and said worked in minutes. The drug she requested would have given her relief by tonight and a new problem within months; the drug she needed would take weeks to help but could keep helping for as long as she needed it. This paper explains the pharmacology behind the choice.

The Diagnosis and Its Measure

Generalized anxiety disorder is defined by excessive, difficult-to-control worry on most days for at least six months, with symptoms such as restlessness, fatigue, poor concentration, irritability, muscle tension and sleep disturbance (Stein & Sareen, 2015). The GAD-7, a seven-item questionnaire, is a validated screening and severity measure; Spitzer et al. (2006) established cut points of 5, 10 and 15 for mild, moderate and severe anxiety. Her score of 15 indicates severe symptoms and provides a baseline for measuring response.

Two Classes, Two Mechanisms

Selective serotonin reuptake inhibitors (SSRIs), such as escitalopram and sertraline, block the serotonin transporter on presynaptic neurons, increasing serotonin in the synapse. The immediate increase is partly offset because more serotonin also activates inhibitory 5-HT1A autoreceptors on serotonergic neurons, reducing their firing. Over two to six weeks, these autoreceptors desensitize, serotonergic transmission increases and downstream changes in receptor sensitivity, gene expression and neural plasticity in circuits involving the amygdala and prefrontal cortex reduce anxiety. This sequence explains the delayed benefit and why some patients feel more jittery in the first week or two.

Serotonin-norepinephrine reuptake inhibitors, such as venlafaxine and duloxetine, add norepinephrine reuptake inhibition and are also first-line options.

Benzodiazepines, such as alprazolam and lorazepam, bind a site between the alpha and gamma subunits of the GABA-A receptor and act as positive allosteric modulators: they increase the frequency with which the chloride channel opens when GABA binds, enhancing inhibitory neurotransmission throughout the brain. The effect is immediate, which is why patients feel calm within minutes. The same widespread inhibition produces sedation, impaired memory and psychomotor slowing, and repeated use leads to receptor adaptations that cause tolerance and physical dependence, with a withdrawal state marked by returning anxiety and poor sleep and, when high doses are stopped abruptly, seizures.

The Evidence

Slee et al. (2019), in a network meta-analysis of randomized trials of drug treatments for generalized anxiety disorder, found that several drugs were more effective than placebo, with duloxetine, pregabalin, venlafaxine and escitalopram showing both efficacy and acceptability, and sertraline showing efficacy with good tolerability. Stein and Sareen (2015) recommend SSRIs or SNRIs, along with cognitive behavioral therapy, as first-line treatment, and they caution against benzodiazepines as first-line long-term therapy because of dependence and adverse effects, particularly in people who use alcohol.

Why Not Alprazolam for Her

Alprazolam is short-acting, which produces rapid relief but also rapid wearing off, rebound anxiety between doses and a higher risk of dependence than longer-acting agents. She drinks wine most evenings, and alcohol and benzodiazepines both enhance GABA-A activity, so together they cause additive sedation and respiratory depression. A benzodiazepine would also treat her symptoms without treating the worry itself and could reinforce avoidance. The FDA requires a boxed warning on benzodiazepines about abuse, misuse, addiction, physical dependence and withdrawal reactions.

The Choice: Escitalopram

Escitalopram was chosen for its evidence in generalized anxiety disorder, its favorable tolerability, its once-daily dosing and its few drug interactions, since it is only a weak inhibitor of cytochrome P450 2D6. She started 5 mg daily for one week, a low dose to reduce early activation, then increased to 10 mg daily, with the option of 20 mg after four to six weeks if response is incomplete. Escitalopram can prolong the QT interval at higher doses, less than citalopram does; she had no cardiac history or interacting drugs, so an electrocardiogram was not needed at this dose.

She was also referred for cognitive behavioral therapy, which has evidence comparable to medication and teaches skills that last after treatment ends. For the first two weeks, while escitalopram takes effect, the nurse practitioner offered hydroxyzine 25 mg at bedtime as needed for sleep and acute anxiety, an antihistamine without dependence risk, and discussed reducing evening alcohol, which worsens sleep and anxiety.

Teaching and Monitoring

The nurse practitioner explained the mechanism in plain language: the medicine changes how brain circuits for worry adapt over several weeks, so it will not work like a sedative, and she may notice better sleep or less tension before the worry itself fades. She described common early side effects, nausea, headache, restlessness and changes in sleep, which usually ease within one to two weeks, and later ones such as sexual side effects, which should be reported rather than tolerated silently. She was told not to stop suddenly, since stopping all at once can bring a few days of lightheadedness, irritability and aching like a mild flu. Although the boxed warning about suicidal thinking applies mainly to people under 25, she was asked to report any worsening mood or thoughts of self-harm.

A follow-up visit was scheduled at four weeks to repeat the GAD-7. A reduction of 50% or more would indicate response; continued treatment for at least six to twelve months after response reduces relapse.

Alternatives If Escitalopram Is Not Enough

The plan anticipated failure as well as success. If she has a partial response at an adequate dose after six to eight weeks, options include increasing to 20 mg, switching to another SSRI or an SNRI such as duloxetine or venlafaxine, or adding buspirone, a 5-HT1A partial agonist with modest anxiolytic effect and no dependence risk. Pregabalin, a calcium channel ligand that dampens excitatory transmitter release, has evidence in generalized anxiety disorder but carries its own misuse potential and sedation. Each alternative follows from a different mechanism, which gives the prescriber more than one pathway to try.

Handling the Request

The conversation mattered as much as the prescription. The nurse practitioner acknowledged that the patient wanted relief quickly and that her suffering was real, explained the trade-offs of benzodiazepines honestly without implying she was seeking to misuse them and offered a plan that included short-term help. The patient agreed to try escitalopram, therapy and hydroxyzine, and asked to revisit the question if she was not better in six weeks.

Conclusion

A woman with severe generalized anxiety asked for a fast-acting benzodiazepine. Understanding how benzodiazepines enhance GABA-A receptor function, and why that produces both rapid relief and tolerance, dependence and dangerous interactions with alcohol, and how SSRIs produce delayed but durable benefit through adaptive changes in serotonergic circuits, led to escitalopram started at a low dose, cognitive behavioral therapy and a nonaddictive option for the first weeks. Pharmacology guided not only the choice of drug but also how to explain it.

References

Slee, A., Nazareth, I., Bondaronek, P., Liu, Y., Cheng, Z., & Freemantle, N. (2019). Pharmacological treatments for generalised anxiety disorder: A systematic review and network meta-analysis. The Lancet, 393(10173), 768-777. https://doi.org/10.1016/S0140-6736(18)31793-8

Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Lowe, B. (2006). A brief measure for assessing generalized anxiety disorder: The GAD-7. Archives of Internal Medicine, 166(10), 1092-1097. https://doi.org/10.1001/archinte.166.10.1092

Stein, M. B., & Sareen, J. (2015). Generalized anxiety disorder. New England Journal of Medicine, 373(21), 2059-2068. https://doi.org/10.1056/NEJMcp1502514